Biomedical applications of L-alanine produced by Pediococcus acidilactici BD16 (alaD+)
Authors:
- 28 January 2022
- journal article
- research article
- Published by Springer Nature in Applied Microbiology and Biotechnology
- Vol. 106 (4) , 1435-1446
Abstract
L-alanine possesses extensive physiological functionality and tremendous pharmacological significance, therefore could be considered as potential ingredient for food, pharmaceutical, and personal care products. However, therapeutic properties of L-alanine still need to be addressed in detail to further strengthen its utilization as a viable ingredient for developing natural therapeutics with minimum side effects. Thus, the present study was aimed to explore the anticipated therapeutic potential of L-alanine, produced microbially using a lactic acid bacterial strain Pediococcus acidilactici BD16 (alaD+) expressing L-alanine dehydrogenase enzyme. The anticipated therapeutic potential of L-alanine was assessed in terms of anti-proliferative, anti-bacterial, and anti-urolithiatic properties. Anti-bacterial assays revealed that L-alanine successfully inhibited growth and in vitro proliferation of important human pathogens including Enterococcus faecalis, Escherichia coli, Klebsiella pneumonia, Staphylococcus aureus, Streptococcus mutans, and Vibrio cholerae in a concentration-dependent manner. Current investigation has also revealed its significant anti-proliferative potential against human lung adenocarcinoma (A549; IC50 7.32 μM) and mammary gland adenocarcinoma (MCF-7; IC50 8.81 μM) cells. The anti-urolithiatic potential of L-alanine was augmented over three different phases, viz., nucleation inhibition, aggregation inhibition, and oxalate depletion. Further, an in vitro cell culture–based kidney stone dissolution model using HEK293-T cells was also established to further strengthen its anti-urolithiatic potential. This is probably the first in vitro cell culture–based model which experimentally validates the immense therapeutic efficacy of L-alanine in treating urolithiasis disease. Key points • Assessment of therapeutic potential of L-alanine produced by LAB. • L-alanine exhibited significant anti-proliferative and anti-bacterial activities. • L-alanine as potential anti-urolithiatic agent.Keywords
This publication has 34 references indexed in Scilit:
- Anticancer activity of small amphipathic β2,2-amino acid derivativesEuropean Journal of Medicinal Chemistry, 2012
- Toxicity of bovicin HC5 against mammalian cell lines and the role of cholesterol in bacteriocin activityMicrobiology, 2012
- Nisin, an apoptogenic bacteriocin and food preservative, attenuates HNSCC tumorigenesis via CHAC1Cancer Medicine, 2012
- Purification, characterization and in vitro cytotoxicity of the bacteriocin from Pediococcus acidilactici K2a2-3 against human colon adenocarcinoma (HT29) and human cervical carcinoma (HeLa) cellsWorld Journal of Microbiology and Biotechnology, 2010
- Further characterization of a bacteriocin produced byLactobacillus paracaseiHL32Journal of Applied Microbiology, 2009
- Characterization of four plasmids harboured in a Lactobacillus brevis strain encoding a novel bacteriocin, brevicin 925A, and construction of a shuttle vector for lactic acid bacteria and Escherichia coliMicrobiology, 2009
- Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR‐MAS spectroscopy of biopsy tissuesMagnetic Resonance in Medicine, 2008
- Interaction of the antimicrobial peptide pheromone Plantaricin A with model membranes: Implications for a novel mechanism of actionBiochimica et Biophysica Acta (BBA) - Biomembranes, 2006
- Bacteriocins: developing innate immunity for foodNature Reviews Microbiology, 2005
- Antimicrobial activities of N-(2-hydroxy-1-naphthalidene)-amino acid(glycine, alanine, phenylalanine, histidine, tryptophane) Schiff bases and their manganese(III) complexesBioMetals, 2004